

14 January 2025

**Graft Polymer (UK) plc**  
("Graft Polymer" or the "Company")

**Announcement of Change of Name to Solvonis Therapeutics plc**

**Graft Polymer (LON:GPL)**, an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce the Company has changed its name to **Solvonis Therapeutics plc**.

A Certificate of Incorporation reflecting the change of name has been issued by Companies House. This change of name, along with the new TIDM of SVNS, will take effect on the Main Market of the London Stock Exchange at 8:00 a.m. on 15 January 2025.

The ISIN and SEDOL numbers for the Company's ordinary shares will remain unchanged as GB00BMD1Z199 and BMD1Z19, respectively.

**Impact on Shareholders**

There will be no impact on shareholders as a result of this name change. Existing share certificates will remain valid, and no action is required from shareholders.

**New Website and Branding**

As part of the rebranding, the Company's website address will change to [www.solvonis.com](http://www.solvonis.com) in due course. The new name, Solvonis Therapeutics plc, reflects the Company's evolving mission to develop novel therapeutics for mental health and substance use disorders.

**Anthony Tennyson, CEO**, commented: "The name Solvonis Therapeutics is derived from the Latin root *solvo*, meaning 'to release, unbind, and free.' This change symbolizes our commitment to freeing individuals from the constraints of mental health and substance use disorders through innovative therapeutic solutions."

"Solvonis Therapeutics plc's new name and direction align with our core mission to improve the lives of those suffering from mental health and addiction conditions, particularly focusing on developing novel treatments that empower patients to regain control of their lives."

**Enquiries:**

**Graft Polymer (UK) plc / Solvonis Therapeutics plc**

Anthony Tennyson, CEO & Executive Director

Email: [anthonytennyson@graftpolymer.co.uk](mailto:anthonytennyson@graftpolymer.co.uk) and also [anthony@solvonis.com](mailto:anthony@solvonis.com)

**Allenby Capital (Financial Adviser and Broker)**

Tel: +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

**About Graft Polymer / Solvonis Therapeutics plc**

Graft Polymer, now transitioning to Solvonis Therapeutics plc, is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for these conditions. Our mission is to improve outcomes for individuals suffering from these disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.

For more information, please visit [www.graftpolymer.co.uk](http://www.graftpolymer.co.uk) and also [www.solvonis.com](http://www.solvonis.com)

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CANUOARVAUAAUR